• Type:
  • Category:

Genomtec sa Elevator Pitch 2022 | Revolutionizing Diagnostics with an Innovative Mobile Molecular Platform with CEO


Company Profile

Discover how Genomtec S.A. is revolutionizing the world of diagnostics with its innovative mobile molecular platform, Genomtec®ID.


CEO Miron Tokarski introduces the company’s mission, technology, and promising future in this comprehensive video presentation. Learn about the executive team driving this groundbreaking project and how their unique point-of-care (POC) analyzer can provide rapid, precise clinical molecular analysis outside traditional laboratory settings. Uncover the development milestones, competitive environment, and planned pipeline for this cutting-edge system, which utilizes proprietary SNAAT® isothermal technology and microfluidic technology to deliver results in as little as 15 minutes.


Dive into the company’s manufacturing process, partnership with international CMOs, and their progress in expanding market authorization and product registration for their SARS-CoV-2 EvaGreen® RT-LAMP diagnostic tests.

Company Profile

Genomtec is an innovative medical technology company dedicated to the development and commercialization of Genomtec®ID – a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.


The company’s flagship project is the Genomtec®ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.


The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution Genomtec®ID will take place in the first half of 2022.


Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.


Genomtec was founded in 2016 and it is headquartered in Wroclaw. More information at: genomtec.com

Genomtec S.A.

Bierutowska 57-59, Budynek 3A

51-317 Wrocław, Poland


  • Introduction
  • Executive Team
  • About Genomtec
  • Our Mission
  • Our Innovation
  • The Technology
  • The Opportunity
  • Planned Pipeline
  • Competitive Environment
  • Development Milestones



Miron Tokarski
CEO & Co-Founder | Genomtec S.A.



This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Elevator Pitches

More Company Presentations

Reviews for Genomtec sa Elevator Pitch 2022 | Revolutionizing Diagnostics with an Innovative Mobile Molecular Platform with CEO

There are currently no reviews for Genomtec sa Elevator Pitch 2022 | Revolutionizing Diagnostics with an Innovative Mobile Molecular Platform with CEO
Scroll to top